-

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Hut 8 Corp. (HUT)

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Hut 8 Corp. (“Hut 8” or the “Company”) (NASDAQ: HUT). The investigation concerns whether Hut 8 and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.

On February 7, 2023, Hut 8 Mining Corp. announced that it was going to merge with U.S. Data Mining Group, Inc. dba US Bitcoin Corp. (“USBTC”) in a $655 million all-stock merger of equals transaction and the combined company would be named Hut 8 Corp. The deal closed on November 30, 2023.

On January 18, 2024, during early trading hours, J Capital Research published a report entitled “The Coming HUT Pump and Dump Management hiding stock ownership through undisclosed related party, a stock-promoter cabal, and a host of left-for-dead assets.” The report alleged that USBTC is backed by promoters with a history of legal issues, one of the major shareholders is an undisclosed related party, USBTC’s core asset is failing to deliver energy and high-speed internet, and USBTC's co-founder has a history of SEC-defined pump-and-dump schemes. On this news, the price of HUT shares declined by $2.16 per share, or approximately 23.28%, from $9.28 per share to close at $7.12 on January 18, 2024.

If you purchased or otherwise acquired Hut 8 securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website: https://www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

Kirby McInerney LLP

NASDAQ:HUT

Release Versions
$Cashtags

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

More News From Kirby McInerney LLP

ADMA INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving ADMA Biologics, Inc.

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:ADMA) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On March 24, 2026, Culper Research published a report on ADMA alleging “Channel Stuffing, an Undisclosed Related Par...

TBRG INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving TruBridge, Inc.

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of TruBridge, Inc. (“TruBridge” or the “Company”) (NASDAQ:TBRG) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On March 16, 2026, TruBridge disclosed that it would be unable to timely file its 2025 Annual Report because “errors...

INVESTOR ALERT: Securities Class Action Filed Against Aldeyra Therapeutics – Investors Encouraged to Contact Kirby McInerney LLP

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Aldeyra Therapeutics (“Aldeyra” or the “Company”) (NASDAQ:ALDX) securities during the period of November 3, 2023 through March 16, 2026, inclusive (“the Class Period”). If you suffered a loss on your Aldeyra investments, you have until May 29, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submitte...
Back to Newsroom